000123910 001__ 123910
000123910 005__ 20240319081029.0
000123910 0247_ $$2doi$$a10.3389/fendo.2022.983792
000123910 0248_ $$2sideral$$a132340
000123910 037__ $$aART-2022-132340
000123910 041__ $$aeng
000123910 100__ $$aGarcia-Rizo, Clemente
000123910 245__ $$aThe effect of early life events on glucose levels in first-episode psychosis
000123910 260__ $$c2022
000123910 5060_ $$aAccess copy available to the general public$$fUnrestricted
000123910 5203_ $$aFirst episode of psychosis (FEP) patients display a wide variety of metabolic disturbances at onset, which might underlie these patients’ increased morbidity and early mortality. Glycemic abnormalities have been previously related to pharmacological agents; however, recent research highlights the impact of early life events. Birth weight (BW), an indirect marker of the fetal environment, has been related to glucose abnormalities in the general population over time. We aim to evaluate if BW correlates with glucose values in a sample of FEP patients treated with different antipsychotics. Two hundred and thirty-six patients were included and evaluated for clinical and metabolic variables at baseline and at 2, 6, 12, and 24 months of follow-up. Pearson correlations and linear mixed model analysis were conducted to analyze the data. Antipsychotic treatment was grouped due to its metabolic risk profile. In our sample of FEP patients, BW was negatively correlated with glucose values at 24 months of follow-up [r=-0.167, p=0.037]. BW showed a trend towards significance in the association with glucose values over the 24-month period (F=3.22; p=0.073) despite other confounders such as age, time, sex, body mass index, antipsychotic type, and chlorpromazine dosage. This finding suggests that BW is involved in the evolution of glucose values over time in a cohort of patients with an FEP, independently of the type of pharmacological agent used in treatment. Our results highlight the importance of early life events in the later metabolic outcome of patients.
000123910 536__ $$9info:eu-repo/grantAgreement/ES/ISCIII/PI20-00661$$9info:eu-repo/grantAgreement/ES/MINECO/PI08-0208$$9info:eu-repo/grantAgreement/ES/MINECO/PI11-00325$$9info:eu-repo/grantAgreement/ES/MINECO/PI14-00612
000123910 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000123910 590__ $$a5.2$$b2022
000123910 592__ $$a1.278$$b2022
000123910 591__ $$aENDOCRINOLOGY & METABOLISM$$b36 / 144 = 0.25$$c2022$$dQ1$$eT1
000123910 593__ $$aEndocrinology, Diabetes and Metabolism$$c2022$$dQ1
000123910 594__ $$a5.6$$b2022
000123910 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000123910 700__ $$aCabrera, Bibiana
000123910 700__ $$aBioque, Miquel
000123910 700__ $$aMezquida, Gisela
000123910 700__ $$0(orcid)0000-0002-9098-655X$$aLobo, Antonio$$uUniversidad de Zaragoza
000123910 700__ $$aGonzalez-Pinto, Ana
000123910 700__ $$aDiaz-Caneja, Covadonga M.
000123910 700__ $$aCorripio, Iluminada
000123910 700__ $$aVieta, Eduard
000123910 700__ $$aBaeza, Inmaculada
000123910 700__ $$aGarcia-Portilla, Maria Paz
000123910 700__ $$aGutierrez-Fraile, Miguel
000123910 700__ $$aRodriguez-Jimenez, Roberto
000123910 700__ $$aGarriga, Marina
000123910 700__ $$aFernandez-Egea, Emilio
000123910 700__ $$aBernardo, Miguel
000123910 700__ $$aPEPs Group
000123910 7102_ $$11007$$2745$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Psiquiatría
000123910 773__ $$g13 (2022), [9 pp.]$$pFront. endocrinol.$$tFrontiers in Endocrinology$$x1664-2392
000123910 8564_ $$s674432$$uhttps://zaguan.unizar.es/record/123910/files/texto_completo.pdf$$yVersión publicada
000123910 8564_ $$s2467771$$uhttps://zaguan.unizar.es/record/123910/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000123910 909CO $$ooai:zaguan.unizar.es:123910$$particulos$$pdriver
000123910 951__ $$a2024-03-18-17:01:48
000123910 980__ $$aARTICLE